SNAP-8 vs FOXO4-DRI
Side-by-side comparison of key properties, dosing, and research.
- Summary
- SNAP-8 is a synthetic octapeptide cosmetic ingredient that reduces the depth of expression lines and wrinkles by competitively inhibiting the SNARE complex involved in acetylcholine release at neuromuscular junctions, providing a topical 'Botox-like' effect.
- FOXO4-DRI is a D-retro-inverso peptide derived from the FOXO4 protein that selectively induces apoptosis in senescent cells. By disrupting the FOXO4-p53 interaction that keeps senescent cells alive, it triggers programmed cell death specifically in these aging, pro-inflammatory cells while sparing healthy tissue.
- Half-Life
- N/A — topical application; local effect duration depends on formulation
- Estimated 2-4 hours (D-amino acid confers resistance to proteolysis)
- Admin Route
- Topical
- Subcutaneous, Intraperitoneal (research)
- Research
- —
- —
- Typical Dose
- 3–10% concentration in formulation
- 5 mg/kg in rodent studies; human equivalent approximately 0.5-1 mg/kg
- Frequency
- 1–2x daily
- 3 consecutive days per cycle
- Key Benefits
- Reduces depth of dynamic expression wrinkles
- Smooths forehead lines, crow's feet, glabellar lines
- Non-invasive topical Botox alternative
- Can be incorporated into serums, creams, eye contour products
- Reduces muscle contraction without paralysis
- Improves skin texture and firmness over time
- Complements other anti-aging peptides (Argireline, Matrixyl)
- Selectively clears senescent cells (senolytics)
- Reduces senescence-associated secretory phenotype (SASP) and chronic inflammation
- Demonstrated restoration of physical fitness in aged mice
- May improve healthspan and reduce age-related tissue dysfunction
- Potential for treatment of age-related pathologies driven by cellular senescence
- Does not affect healthy non-senescent cells at therapeutic doses
- Side Effects
- Generally excellent tolerability
- Rare: mild redness in sensitive individuals
- Not suitable for injection (topical use only)
- Limited human data; largely preclinical evidence
- Possible temporary inflammatory response as senescent cells are cleared (senolytic effect)
- Weight loss observed at high doses in rodent studies
- Unknown long-term safety profile in humans
- Stacks With
- —
- —